^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Non-Squamous Non-Small Cell Cancer

    Related cancers:
    1d
    A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC (clinicaltrials.gov)
    P2, N=80, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression
    |
    Keytruda (pembrolizumab) • trastuzumab brengitecan (BL-M07D1)
    1d
    AcceleRET Lung: A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=223, Terminated, Hoffmann-La Roche | Completed --> Terminated; Early termination of the study resulted from organizational and commercial decisions that led to the discontinuation of pralsetinib's global marketing and development in all territories (excluding US and Greater China).
    Trial termination
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • Gavreto (pralsetinib)
    1d
    U31402-A-U102: U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=312, Active, not recruiting, Daiichi Sankyo | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS mutation • KRAS G12C • EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR L861Q • ROS1 fusion • EGFR G719X • KRAS G12
    |
    patritumab deruxtecan (U3-1402)
    1d
    An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) (clinicaltrials.gov)
    P2, N=36, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Aug 2026
    Enrollment closed • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR wild-type • ALK wild-type
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    1d
    A Phase II Study of ILKN421H With Pembrolizumab in Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, iLeukon Therapeutics, Inc.
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab)
    2d
    HARMONi-A: Phase 3 Clinical Study of AK112 for NSCLC Patients (clinicaltrials.gov)
    P3, N=322, Active, not recruiting, Akeso | Trial completion date: Nov 2025 --> Sep 2026
    Trial completion date
    |
    EGFR mutation
    |
    carboplatin • pemetrexed • Yidafan (ivonescimab)
    2d
    TROPION-Lung17: Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations (clinicaltrials.gov)
    P3, N=82, Recruiting, AstraZeneca
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    KRAS G12C • MET exon 14 mutation • KRAS G12
    |
    docetaxel • Datroway (datopotamab deruxtecan-dlnk)
    2d
    KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) (clinicaltrials.gov)
    P2, N=43, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting | N=24 --> 43
    Enrollment open • Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • pemetrexed • calderasib (MK-1084)
    3d
    A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=254, Recruiting, Shanghai Henlius Biotech | Active, not recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    PD-L1 expression • EGFR mutation • EGFR negative
    3d
    AK117-202: A Study of AK112 in Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=154, Completed, Akeso | N=250 --> 154 | Trial completion date: Jun 2026 --> Dec 2025 | Trial primary completion date: May 2025 --> Nov 2025 | Active, not recruiting --> Completed
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Yidafan (ivonescimab) • ligufalimab (AK117)
    3d
    HARMONi: Phase III Study of AK112 for NSCLC Patients (clinicaltrials.gov)
    P3, N=420, Active, not recruiting, Summit Therapeutics | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    EGFR mutation • EGFR exon 19 deletion • EGFR T790M
    |
    carboplatin • pemetrexed • Yidafan (ivonescimab)
    4d
    CCTG BR34: Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC (clinicaltrials.gov)
    P2, N=301, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • NKX2-1 (NK2 Homeobox 1) • TP63 (Tumor protein 63)
    |
    EGFR mutation • ALK fusion
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)